Travere Therapeutics said Tuesday it plans to ask the FDA for approval of its kidney drug Filspari in a rare condition known as focal segmental glomerulosclerosis, or FSGS, using a secondary endpoint ...

Chinese API manufacturers Wuhu Nuowei Chemistry and Chengdu Innovation Pharmaceutical have been placed on US import alert ...

Health acquires Caraway Health, merging pediatric urgent care with Gen Z virtual care. The deal is another tying together two ...

Major pharma firms like Eli Lilly, GSK, Merck, Regeneron and Sanofi announce $35B+ in share buybacks since December, ...

Inventiva is trimming its pipeline and enacting layoffs in an effort to get its lead MASH drug approved, the company ...

Several brand-name drugmakers believe they will withstand any drug pricing impacts from President Donald Trump’s tariffs — ...

Leaked Pfizer Phase 1 trial shows mevrometostat plus Xtandi reduced prostate cancer progression risk by 49%. Data sparked ...

Novartis acquires Anthos' abelacimab for $925M upfront and up to $3.1B total, marking CEO Bill Meury's second major exit and ...

Vertex chief operating officer Stuart Arbuckle plans to retire in July, the company announced Monday afternoon. He will be ...

A federal court in Massachusetts temporarily blocked the Trump administration’s new cap on indirect cost reimbursements for ...

German pharma company Merck KGaA confirmed that it is in talks to acquire SpringWorks Therapeutics, though a deal has yet to ...

Eli Lilly is betting up to $630 million on an experimental MASH treatment from a South Korean biotech. The pharma giant ...